1) NIH BOS Montelukast trial (LAI): 22 patients enrolled to date. 19 patients have completed the primary endpoint. Interim analysis will be conducted this summer and analysis of immunological endpoints ongoing. 2) FHCRC new onset BOS trial (chair): open at NIH, one patient accrued at NIH. 3) Lung consortium trial: in development. 4) cGVHD myositis study of respiratory muscle: manuscript published. 5) AI ON CGVHD Natural history study. Manuscript on PFT function equations in submission.
|Williams, K M; Ostrow, L W; Loeb, D M et al. (2012) Immunohistochemistry of affected tissue may guide cGVHD treatment decisions. Bone Marrow Transplant 47:731-3|
|Norman, B C; Jacobsohn, D A; Williams, K M et al. (2011) Fluticasone, azithromycin and montelukast therapy in reducing corticosteroid exposure in bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: a case series of eight patients. Bone Marrow Transplant 46:1369-73|
|Chien, Jason W; Duncan, Steven; Williams, Kirsten M et al. (2010) Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation-an increasingly recognized manifestation of chronic graft-versus-host disease. Biol Blood Marrow Transplant 16:S106-14|